Use of a New Hormone Formulation in Fertility Treatments
Author Information
Author(s): Klaus Bühler, Olaf Naether
Primary Institution: Centre for Reproductive Medicine and Gynaecological Endocrinology, Langenhagen, Germany
Hypothesis
Can a 2:1 formulation of follitropin alfa and lutropin alfa improve outcomes in assisted reproductive technology?
Conclusion
The study found that the 2:1 formulation is effective for achieving clinical pregnancies and has a positive safety profile.
Supporting Evidence
- The clinical pregnancy rate per transfer was 27.5%.
- Three cases of ovarian hyperstimulation syndrome were reported, with one requiring hospitalization.
- 90.7% of cycles used the 2:1 formulation throughout the stimulation period.
Takeaway
Doctors used a new hormone mix to help women get pregnant, and it worked well and was safe.
Methodology
An observational, post-marketing surveillance study analyzing data from ART cycles over 11 months.
Potential Biases
Potential variability in responses due to subjective definitions used by different clinicians.
Limitations
Data sets were incomplete, and definitions of 'poor response' may vary among physicians.
Participant Demographics
58.7% of patients were aged 35 or older, with many undergoing their first ART cycle.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website